Airsonett AB

Thank you for helping to make 2024 such an exciting, productive, and rewarding year.    Close to 1,000 patients in Sweden now receive TLA treatment for severe allergic asthma and atopic dermatitis, making TLA the leading treatment for this patient group.    Throughout the year, we’ve met with the asthma and allergy care profession in Sweden, at Network meetings, ASTA in Linköping, ALLISS in Båstad and Lund, BLFaol in Stockholm, SFFA in Linköping, and of course, at many clinics all along Sweden. It is incredibly warming to hear your stories about how TLA has wholly changed patients’ everyday lives:    “One of our patients had such bad eczema that she didn’t dare go on a date… Now, she has completely changed, and she really enjoys her new dating life.”  Quote from a Swedish Caregiver  We have had an intensive year focused on our continuous effort to bring TLA treatment to more patients in new European countries. We’re making significant progress in Finland and Norway, where we’ve had many good meetings and discussions with leading local allergy key opinion leaders. Several patients are receiving TLA treatment in both countries, and the interest is fast-growing. In Norway, the Norwegian Asthma and Allergy Association's magazine recently published an article about Christine, one of the first Norwegian patients to receive TLA treatment for her allergic asthma.    In Holland, we are working with local partners Mudita Medical and are in close discussions with both the allergy care profession and insurance companies. There is growing excitement about TLA treatment and how it can be implemented in their healthcare system.    Our partners in Italy, Innovacaremd, have done impressive work to create interest in TLA treatment in several of the Italian healthcare regions, and there is a growing number of patients already receiving TLA treatment. Airsonett was also showcasing at the SIMRI and SIAAIC Congresses together with InnovacareMD. We had an exciting study being presented at the European Academy of Allergy and Clinical Immunology - EAACI Congress in Valencia, Spain, in May, where it received the Award for Outstanding Poster Presentation. It demonstrates the significant efficacy of Airsonett's TLA technology in reducing airborne allergens such as cat dander, grass pollen, and house dust mite allergens in the breathing zone. The results show a remarkable reduction in allergen levels, with the concentration of allergens in the breathing zone falling below detectable limits.   We have several other promising studies currently underway, including one pediatric study in the UK, where we hope to be able to present the results late next year.      From all of us at Airsonett to all patients, caregivers, and partners – we want to thank you for 2024, and we look forward to 2025! Merry Christmas and a Happy New Year!

Greetings from Bodø, Norway, where we participate at the Fall Meeting organized by the Norwegian Association for Pulmonary Medicine NFL - Norsk Forening for Lungemedisin. This is a valuable opportunity to engage with Norway’s leading professionals in pulmonary care. Martin Dahl is sharing his insights on how Airsonett TLA (Temperature-controlled Laminar Airflow) improves the lives of patients with allergic asthma and atopic dermatitis. We are thrilled to see the growing interest in TLA treatment in Norway and other countries. Please reach out if you want to know more!  #asthma #allergy #medtech #PulmonaryMedicine #RespiratoryHealth #Airsonett

Today, Airsonett is participating in the ALLISS Fall meeting at the Grand Hotel in Lund, Sweden. This event is organized by the Allergology Interest Association in South Sweden, and the program has interesting sessions like “The blocked nose - many facets of a common problem” by Professor Dame Valerie J Lund, DBE and “Eosinophilic granulomatosis with polyangiitis, EGPA– clinical phenotypes and modern management” by Aladdin Mohammad, Associate Professor and Senior Consultant in Rheumatology at Lund University Hospital. Our team, including Malin Prahl and Martin Dahl is here, discussing how Temperature-controlled Laminar Airflow (TLA) makes a difference for patients with allergic asthma and atopic dermatitis with both familiar and new faces. Thank you ALLISS for organizing this important and inspiring meeting!  #ALLISS #Airsonett #AsthmaCare #AllergyTreatment #TLA #allergy #asthma

Last week, Airsonett was proudly represented at the Italian National SIMRI Congress in Turin by our esteemed partner, Innovacaremd. This congress, organized by the Italian Society for Pediatric Respiratory Diseases (SIMRI), centered around the theme, “Breath: Science and Therapy for Children’s Health,” focusing on severe asthma. We are honored to be featured at such a prestigious event, bringing together over 300 attendees, including key opinion leaders in respiratory health from Italy and abroad. It is exciting to see the growing interest in Temperature-controlled Laminar Airflow (TLA) as a novel treatment for severe allergic asthma in Italy. We are optimistic that more Italian patients will soon experience an improved quality of life through TLA therapy. Thank you to Innovacaremd, Marco Scorsato, and Alessandra Perale for your collaboration and dedication! #SIMRI #Asthma #Allergy #Pediatric #Respiratory #Airsonett

We're #hiring a new Finance Manager in Sweden. Apply today or share this post with your network.

We're #hiring a #finance manager in Sweden. Know the perfect candidate? Please spread the word 🙏🏼

Airsonett will be at the National SIMRI Congress in Turin this week, October 10-12. Our Italian partners Innovacaremd will represent us at this important congress, organized by SIMRI (Italian Society for Pediatric Respiratory Diseases). The theme for the congress is "Breath: Science and Therapy for Children's Health", focusing primarily on severe asthma. We look forward to even more pediatricians in Italy learning about the benefits and clinical effects of TLA (Temperature-controlled Laminar Airflow). Reda more about the SIMRI congress here: https://lnkd.in/d2TtTKcV Marco Scorsato Alessandra Perale #asthma #allergy #atopicdermatitis #Allergycare #healthcare #SIMRI 

Congratulations to Christina West and her team for receiving the prestigious SFFA 2024 grant! Their research project, Restoration of Microbiota in Neonates: A Randomized Controlled Trial, aims to explore if allergies can be prevented in children born via C-section. We are excited to see the results of this innovative study! Thank you, Erik Melén, for inviting us to sponsor this grant, along with our fellow sponsors AstraZeneca, ALK, Chiesi Group, GSK, Orionpharma, Sanofi, and Viatris. We are proud to help make important allergy research projects like these possible, paving the way for a healthier future! #ResearchMatters #InnovationInHealthcare #PreventingAllergies #Airsonett #SFFA2024 #MicrobiotaRestoration

Today, we’re at #SFFA in Linköping, Sweden, where Daniel Raffensperger and Solveig Foss Westergren are representing Airsonett and talking about the powerful impact of TLA treatment on patients with severe allergic diseases. Thanks to Chiesi for the interesting session with Professor Omar Usmani on "The importance of small airways in asthma inflammatory patterns and dysfunction". We all learned a lot! #asthma #allergy #atopicdermatitis #Allergycare #healthcare #Airsonett

Greetings from the #BLFaol Fall Meeting in Stockholm! Malin Prahl, Daniel Raffensperger, and Solveig Foss Westergren represent Airsonett at this event, which is organized by the Swedish Paediatric Society for Allergy and Pulmonology. They share their expertise on TLA (Temperature-controlled Laminar Airflow) treatment and its transformative impact on patients suffering from severe allergic diseases. Curious about how TLA can benefit your patients or want to explore the extensive scientific data backing its effectiveness? Let’s connect and arrange a meeting to tell you and your clinic more. #asthma #allergy #atopicdermatitis #Allergycare #healthcare